



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1614/51

Applicant: Dennis A. Carson et al.

Title: USE OF ETODOLAC IN THE TREATMENT OF CANCER

Docket No.: 103.021US1

Serial No.: 09/589,476

Filed: June 7, 2000

Due Date: N/A

Examiner: Donna A. Jagoe

Group Art Unit: 1614

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ A return postcard.
- ☒ A Communication Concerning Related Applications (2 pgs.).
- ☒ A Supplemental Information Disclosure Statement (1 pg.), Form 1449 (2 pgs.), and copies of 45 cited documents.
- ☒ A check in the amount of \$180.00 to cover the fee for consideration of Information Disclosure Statement under 97(c).

Please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

Customer Number 21186

By: William F. Prout
Atty: William F. Prout
Reg. No. 33,995

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 16 day of November, 2004.

Nicole [Signature]


Name

[Signature]

Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

(GENERAL)



S/N 09/589,476

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dennis A. Carson et al.

Examiner: Donna A. Jagoe

Serial No.: 09/589,476

Group Art Unit: 1614

Filed: June 7, 2000

Docket: 103.021US1

Title: USE OF ETODOLAC IN THE TREATMENT OF CANCER

COMMUNICATION CONCERNING RELATED APPLICATIONS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Applicants would like to bring to the Examiner's attention the following related applications in the above-identified patent application:

<u>Serial/Patent No.</u>	<u>Filing Date</u>	<u>Attorney Docket</u>	<u>Title</u>
09/360,020 6,545,034	July 23, 1999	103.014US1	USE OF ETODOLAC FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
10/236,221	September 5, 2002	103.014US2	USE OF ETODOLAC FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
10/753,665	January 8, 2004	103.014US3	USE OF ETODOLAC FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
09/634,207	August 9, 2000	103.022US1	INDOLE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER
10/667,208	September 19, 2003	103.032US1	USE OF ETODOLAC TO TREAT HYPERPLASIA
10/682,790	October 9, 2003	103.038US1	INDOLE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER

COMMUNICATION CONCERNING RELATED APPLICATIONS

Serial Number: 09/589,476

Filing Date: June 7, 2000

Title: USE OF ETODOLAC IN THE TREATMENT OF CANCER

Page 2

Dkt: 103.021US1

Respectfully submitted,
DENNIS A. CARSON ET AL.


By Applicants' Representatives,
SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6968

Date November 16, 2004 By William F. Prout
William F. Prout
Reg. No. 33,995

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 16 day of November, 2004.

NEURON
Name

[Signature]
Signature



SA 09/589,476

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dennis A. Carson et al.

Examiner: Donna A. Jagoe

Serial No.: 09/589,476

Group Art Unit: 1614

Filed: June 07, 2000

Docket: 103.021US1

Title: USE OF ETODOLAC IN THE TREATMENT OF CANCER

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(2), Applicants have included the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 19-0743.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,
DENNIS A. CARSON ET AL.

11/22/2004 AMONDAF1 00000013 09589476

01 FC:1806

180.00 OP

By their Representatives,
SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6968

Date November 16, 2004By William F. Prout

William F. Prout

Reg. No. 33,995

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 16 day of November, 2004.


Nicole [Signature]
Name

[Signature]
Signature

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	09/589,476
Filing Date	June 7, 2000
First Named Inventor	Carson, Dennis
Group Art Unit	1614
Examiner Name	Jagoe, Donna

Sheet 1 of 2

Attorney Docket No: 103.021US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-2002/0042375A1	04/11/2002	Heimbrook, D. C., et al.	06/29/2001
	US-2003/0004142A1	01/02/2003	Prior, C. P., et al.	04/17/2002
	US-2003/0004143A1	01/02/2003	Prior, C. P., et al.	04/18/2002
	US-3,053,255	09/11/1962	Meyer, Friedrich	12/16/1958
	US-3,710,795	01/16/1973	Higuchi, Takeru, et al.	09/29/1970
	US-3,843,480	10/22/1974	Dreher, Donald F.	12/04/1967
	US-3,939,178	02/17/1976	Demerson, Christopher A., et al.	09/15/1972
	US-3,948,254	04/06/1976	Zaffaroni, Alejandro	08/28/1974
	US-3,948,262	04/06/1976	Zaffaroni, Alejandro	03/10/1975
	US-3,974,179	08/10/1976	Demerson, Christopher A., et al.	10/10/1974
	US-3,993,073	11/23/1976	Zaffaroni, Alejandro	03/03/1975
	US-4,310,509	01/12/1982	Berglund, Claire A., et al.	07/31/1979
	US-4,460,562	07/17/1984	Keith, Alec D., et al.	03/30/1983
	US-4,466,953	08/21/1984	Keith, Alec D., et al.	09/30/1982
	US-4,482,534	11/13/1984	Blank, Izhak	08/18/1983
	US-4,485,097	11/27/1984	Bell, E.	05/25/1983
	US-4,505,891	03/19/1985	Ito, Toshio	
	US-4,533,540	08/06/1985	Blank, Izhak	08/30/1984
	US-4,542,012	08/17/1985	Dell, John D.	02/11/1983
	US-4,542,013	09/17/1985	Keith, Alec D., et al.	08/16/1983
	US-4,560,555	12/24/1985	Snider, Bruno	12/12/1983
	US-4,585,877	04/29/1986	Demerson, Christopher A., et al.	05/06/1985
	US-4,597,961	07/01/1986	Etscorn, Frank T.	01/23/1985
	US-4,608,249	08/26/1986	Otsuka, Saburo	11/02/1982
	US-4,686,213	08/11/1987	Ferdinandi, Eckhardt S., et al.	08/15/1986
	US-4,748,252	05/31/1988	Ferdinandi, Eckhardt S., et al.	01/28/1987
	US-4,806,356	02/21/1989	Shaw, Alec S.	04/03/1987
	US-4,940,587	07/10/1990	Jenkins, Anthony W., et al.	06/03/1986
	US-5,599,946	02/04/1997	Vincenzo, Giobbio, et al.	05/30/1995
	US-5,776,967	07/07/1998	Kreft, Anthony F., et al.	07/07/1997
	US-5,824,699	10/20/1998	Kreft, Anthony F., et al.	03/16/1998
	US-5,968,974	10/19/1999	Kargman, Stacia, et al.	10/10/1997
	US-5,981,592	11/09/1999	Wechter, W. J., et al.	04/09/1998
	US-6,160,018	12/12/2000	Wechter, William J., et al.	03/10/1997

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	09/589,476
Filing Date	June 7, 2000
First Named Inventor	Carson, Dennis
Group Art Unit	1614
Examiner Name	Jagoe, Donna

Sheet 2 of 2

Attorney Docket No: 103.021US1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
	WO-0106990A2	02/01/2001	Carson, Dennis A.	
	WO-0212188A2	02/14/2002	Carson, Dennis A.	
	WO-9748391A3	12/24/1997	Xiaotao, Quian	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HEATH, CLARK W., "Nonsteroidal Antiinflammatory Drugs and Human Cancer", <u>American Cancer Society, Volume 74, Number 10</u> , (November 15, 1994),2885-2886	
		MCCRACKEN, JOHN D., "Antiproliferative Effects of the Enantiomers of Flurbiprofen", <u>Journal of Clinical Pharmacology</u> , (1996),540-545	
		PIAZZA, GARY A., "Apoptosis Primarily Accounts for the Growth-inhibitory Properties of Sulindac Metabolites and Involves a Mechanism That is Independent of Cyclooxygenase Inhibition, Cell Cycles Arrest, and p53 Induction", <u>Cancer Research, Volume 57</u> , (June 15, 1997),2452-2459	
		RILEY, et al., "New Drugs: a six month review", <u>US Pharmacist, Vol. 16</u> , (September 1991),35-64	
		THUN, MICHAEL J., "Aspirin, NSAIDs, and digestive tract cancers", <u>Cancer and Metastasis Reviews 13</u> , Kluwer Academic Publishers., (1994),269-277	
		WECHTER, WILLIAM J., "R-Flurbiprofen (E-7869), a chemopreventive and treatment of cancer", <u>Inflammopharmacology, Volume 8, No. 2</u> , (2000),189-206	
		WECHTER, WILLIAM J., "R-Flurbiprofen Chemoprevention and Treatment of Intestinal Adenomas in the APC min/+ Mouse Model: Implications for Prophylaxis and Treatment of Colon Cancer", <u>Cancer Research, Volume 57, Number 19</u> , (October 1, 1997),4316-4324	
		WECHTER, WILLIAM J., "Rac-Flurbiprofen Is More Ulcerogenic Than Its (S)-Enantiomer", <u>Chirality, Volume 5, Number 7</u> , (1993),492-494	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached